LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Fziomed Announces FDA 510(k) Clearance for Dynavisc® Tendon Protector in the United States
Legal & Regulatory and Reimbursement

Fziomed Announces FDA 510(k) Clearance for Dynavisc® Tendon Protector in the United States

By Carl StearnsNovember 18, 2026 2 min read Premium comments

Advertisement

Fziomed Announces FDA 510(k) Clearance for Dynavisc® Tendon Protector in the United States
Photo courtesy of Fziomed

SAN LUIS OBISPO, Calif., Nov. 18, 2026 /PRNewswire/ -- Fziomed, Inc. ("Fziomed" or the "Company"), a global leader in postsurgical adhesion prevention biomaterials and surgical innovation, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Dynavisc® Tendon Protector. Dynavisc is a fully synthetic, ready-to-use, absorbable gel designed to protect tendons, ligaments, and skeletal muscle following surgical procedures.

Developed using Fziomed's proprietary dual-polymer technology, Dynavisc is a clear, absorbable gel applied directly to the surgical site following tendon repair. Dynavisc coats exposed tissues, creating a temporary physical barrier that separates and protects adjacent tissues during the healing process, which may aid in reducing postoperative pain, preserving range of motion, and supporting functional recovery.

"FDA clearance of Dynavisc represents another important milestone for Fziomed as we continue expanding our portfolio of innovative biomaterial technologies in the United States," said Ryan Bledsoe, Vice President of Marketing and Market Access at Fziomed. "Dynavisc has a long history of clinical use internationally, and we are excited to bring this established technology to the U.S. market. Its fully synthetic composition, ready-to-use formulation, and ease of application offer surgeons a compelling and differentiated alternative solution for tissue separation and protection following tendon repair procedures."

Dynavisc has been commercially available internationally for more than a decade and has been used in the treatment of more than 50,000 patients worldwide. Its established clinical history is supported by multiple peer-reviewed clinical publications evaluating functional outcomes, tissue gliding, and tendon healing following surgical procedures.

"In tendon surgery, the repair itself is only half the battle. Postoperative scar tissue that restricts tendon gliding is one of the most common reasons a good repair ends with a compromised functional outcome," said Nicholas Caggiano, MD, Orthopedic Hand Surgeon at Central Coast Orthopedic Medical Group (San Luis Obispo, CA). "Having a gel technology that creates a temporary protective barrier between tissues is a valuable addition to our surgical options. Dynavisc is particularly appealing because its ready-to-use gel formulation allows for straightforward application and seamless integration into the surgical workflow."

The FDA clearance of Dynavisc further advances Fziomed's commitment to bringing established biomaterial technologies to U.S. surgeons and expanding solutions designed to address postsurgical complications across multiple surgical specialties.

About Fziomed, Inc.

Pioneering biomaterials since 1996 and having helped more than 1 million patients globally, Fziomed is a recognized global leader in postsurgical adhesion prevention, focused on addressing unmet clinical needs in spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures. Fziomed develops, manufactures, and commercializes best-in-class surgical biomaterials used by clinicians to Preserve Surgical ExcellenceSM and improve patient outcomes.

Fziomed's synthetic, absorbable gel formulations are based on the Company's proprietary dual-polymer technology platform that provide a temporary, physical separation of tissues during the body's natural healing process – reducing adhesion formation. Fziomed's portfolio of adhesion barrier products are marketed in more than 70 countries under various brand names and have been used clinically since 2002.

Fziomed is headquartered in San Luis Obispo, California, and has been named one of the Best Places to Work in Southern California for the past four consecutive years.

Visit fziomed.com to learn more about Fziomed and our industry-leading products.

SOURCE Fziomed, Inc.

Author

CS
Carl Stearns

Why This Matters

Two Perspectives

MBA Lens: Economic and industry impact

Fziomed secured FDA 510(k) clearance for Dynavisc Tendon Protector, expanding its U.S. portfolio of synthetic biomaterials. This strategic move leverages Dynavisc's international clinical history and ready-to-use formulation, offering a differentiated solution for surgeons. The clearance enhances Fziomed's market presence in postsurgical adhesion prevention, potentially driving adoption through ease of use and established efficacy, impacting competitive dynamics in the orthopedic surgical market.

  • The FDA clearance allows Fziomed to expand its U.S. market access with an established, internationally proven product.
  • Dynavisc's ready-to-use, synthetic gel formulation offers a compelling, differentiated alternative for surgeons, potentially aiding adoption.

PhD Lens: Clinical and outcomes impact

Dynavisc Tendon Protector, a fully synthetic, absorbable gel, received FDA 510(k) clearance. Developed with Fziomed's proprietary dual-polymer technology, it forms a temporary physical barrier at surgical sites to separate and protect adjacent tissues during healing. This mechanism aims to reduce postoperative pain, preserve range of motion, and support functional recovery following tendon repair procedures, building on over a decade of international clinical use.

  • The dual-polymer technology creates a temporary physical barrier, preventing adhesion formation and supporting tissue separation.
  • Clinical history from over 50,000 international patients and peer-reviewed publications support functional outcomes and tissue gliding.
React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy